OncoZenge

OncoZenge is a clinical-stage biotech developing BupiZenge™, a novel lozenge formulation of the anesthetic bupivacaine for the localized treatment of oral mucositis pain. The product has successfully completed Phase 1 and 2 trials and has received regulatory guidance from the FDA and EMA, with Phase 3 planning underway. The company is targeting a large global market with no approved therapeutic treatments, positioning BupiZenge™ as a potential first-in-class, non-opioid solution that could significantly improve patient quality of life and reduce systemic opioid use.

Proprietary lozenge formulation for localized, topical delivery of the anesthetic bupivacaine directly to the oral mucosa.

The therapeutic landscape for oral mucositis is currently sparse with no approved pharmaceutical treatments, placing OncoZenge as a potential first-mover. Competition consists of generic palliative care (oral rinses, opioids) and other investigational agents in earlier development, but BupiZenge™'s advanced clinical stage and localized mechanism differentiate it.